Showing 15 posts of 91 posts found.


FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

August 25, 2023
Medical Communications FDA, MS, Neurology, Sandoz

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …


Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …


FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021
Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …


Roche to start new trials of Ocrevus to defend multiple sclerosis franchise

September 9, 2020
Research and Development MS, MS drug, Roche

Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …


Sanofi to buy Principia Biopharma for $3.4 billion

August 17, 2020
Sales and Marketing MS, Sanofi

Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …

Novartis releases results of MS drug trials weeks ahead of FDA verdict

May 28, 2020
Business Services MS, Novartis

Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …


FDA approves MS drug for human trials

January 27, 2020
Sales and Marketing MS, MS symptoms, MS treatment, Neuro, neurology

A drug that can make it easier to diagnose Multiple Sclerosis (MS) has been approved for its first human trials …


Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019
Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …


MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

July 25, 2019
Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …


Novartis’ new MS drug to cost $88,000 a year

March 27, 2019
Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …


Drug slows brain shrinkage associated with progressive multiple sclerosis, study shows

August 30, 2018
Research and Development MS, brain, ibudilast, neuroscience, research

The multiple sclerosis drug ibudilast, slowed brain shrinkages in patients with progressive MS, a study published in the New England …


Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS

June 22, 2018
Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma

Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

Latest content